Jasper Therapeutics, Inc. (JSPR) - Dilution Analysis

10-Q filing | 28.7M shares outstanding

10-K filing | 28.0M shares outstanding

10-Q filing | 28.0M shares outstanding

10-Q filing | 15.3M shares outstanding

10-Q filing | 15.0M shares outstanding

S-3 filing: Jasper Therapeutics, Inc. files an S-3 form to offer Common Stock, Preferred Stock, Debt Securities, and Depositary Shares with an aggregate initial offering price not to exceed $300,000,000.

10-K filing | 14.6M shares outstanding

10-Q filing | 15.0M shares outstanding

10-Q filing | 15.0M shares outstanding

10-Q filing | 15.1M shares outstanding

10-K filing | 15.1M shares outstanding

8-K filing: Stock split 1-for-10 | Outstanding: 109,720,741 → 10,972,074

10-Q filing | 109.7M shares outstanding

10-Q filing | 109.2M shares outstanding

10-Q filing | 110.3M shares outstanding

S-3 filing: Jasper Therapeutics, Inc. is filing a shelf registration statement for the potential sale of up to $250,000,000 in various securities, including common stock, preferred stock, and debt securities. The company may offer and sell the securities from time to time, through agents, underwriters, brokers, or dealers.

10-K filing | 109.4M shares outstanding

10-Q filing | 36.6M shares outstanding

S-3 filing: Jasper Therapeutics, Inc. files an S-3 registration statement for a mixed shelf offering of common stock, preferred stock, debt securities, warrants, rights, units and depositary shares, with an aggregate offering price not to exceed $150,000,000.

POS AM filing: This is a POS AM filing registering the resale of common stock by selling stockholders and the issuance of common stock upon the exercise of public warrants.

10-Q filing | 36.7M shares outstanding

10-Q filing | 36.6M shares outstanding

POS AM filing: This POS AM filing relates to the resale of 33,081,493 shares of voting common stock by selling stockholders and the issuance and resale of up to 4,999,883 shares of common stock upon the exercise of outstanding warrants.

10-K filing | 36.6M shares outstanding

10-Q filing | 36.6M shares outstanding

S-1 filing: This S-1 filing registers shares of Voting Common Stock for resale by selling stockholders and shares issuable upon exercise of outstanding warrants.

8-K filing: AMHC sold 10,000,000 shares of Class A Common Stock to PIPE Investors at $10.00 per share for gross proceeds of $100.0 million. ($100.0M proceeds)

8-K filing: AMHC stockholders approved the Business Combination, 9,262,099 shares of Class A Common Stock were redeemed, Jasper waived the Minimum Cash Condition, and the Sponsor agreed to adjustments to the earnout and forfeiture of 200,000 Class B shares, receiving 2,300,000 shares of New Jasper Voting Common Stock.

10-Q filing | 10.0M shares outstanding

10-Q filing | 10.0M shares outstanding

8-K filing: Amplitude Healthcare Acquisition Corporation entered into a business combination agreement with Jasper Therapeutics, Inc., where Merger Sub will merge with and into Jasper, with Jasper surviving as a wholly-owned subsidiary of the Company, with an equity value of $275.0 million and the PIPE Investors have agreed to subscribe for and purchase an aggregate of 10,000,000 Company Shares at a price of $10.00 per share, for aggregate gross proceeds of $100.0 million. ($100.0M proceeds)

10-K filing | 10.0M shares outstanding

10-Q filing | 10.0M shares outstanding

10-Q filing | 2.5M shares outstanding

10-Q filing | 2.5M shares outstanding

10-K filing | 2.9M shares outstanding

8-K filing: On January 3, 2019, 375,000 shares of Class B Common Stock were forfeited by the Sponsor, and such forfeited shares were cancelled by the Company.